TITLE

Increased levels of vascular endothelial growth factor in aqueous humor of patients with diabetic retinopathy: Is it the whole truth?

AUTHOR(S)
Gopal, K. S. Santhan
PUB. DATE
September 2011
SOURCE
Indian Journal of Ophthalmology;Sep2011, Vol. 59 Issue 5, p405
SOURCE TYPE
Academic Journal
DOC. TYPE
Letter
ABSTRACT
A letter to the editor is presented in response to the article "Increased levels of vascular endothelial growth factor in the aqueous humor of patients with diabetic retinopathy," by K. M. Selim and colleagues in the 2010 issue.
ACCESSION #
64735843

 

Related Articles

  • Biomarkers in Diabetic Retinopathy and the Therapeutic Implications. Zorena, Katarzyna; Raczyńska, Dorota; Raczyńska, Krystyna // Mediators of Inflammation;2013, Vol. 2013, p1 

    The main problem both in type 1 (T1DM) and type 2 (T2DM) diabetes is the development of chronic vascular complications encompassing micro- as well as macrocirculation. Chronic complications lower the quality of life, lead to disability, and are the cause of premature death in DM patients. One of...

  • Plasma VEGF levels may not accurately reflect the truth all the time. Şendur, Mehmet; Aksoy, Sercan; Yaman, Şebnem; Arık, Zafer; Özdemir, Nuriye; Zengin, Nurullah // Medical Oncology;Jun2012, Vol. 29 Issue 2, p1403 

    A letter to the editor is presented in response to a study by She-Juan An et al. about the link between low posttreatment vascular endothelial growth factor (VEGF) levels and the overall survival of cancer patients, which was published in a 2011 issue.

  • APE1/Ref-1Role in Redox Signaling: Translational Applications of Targeting the Redox Function of the DNA Repair/Redox Protein APE1/Ref-1. Kelley, Mark R.; Georgiadis, Millie M.; Fishel, Melissa L. // Current Molecular Pharmacology;Jan2012, Vol. 5 Issue 1, p36 

    The heterogeneity of most cancers diminishes the treatment effectiveness of many cancer-killing regimens. Thus, treatments that hold the most promise are ones that block multiple signaling pathways essential to cancer survival. One of the most promising proteins in that regard is APE1, whose...

  • IL-4, IL-6, IL-10, IL-17A and vascular endothelial growth factor in the vitreous of patients with proliferative diabetic retinopathy. Chernykh, Valery; Smirnov, Evgeny; Varvarinsky, Yegor; Chernykh, Dmitry; Obukhova, Olga; Trunov, Aleksandr // Advances in Bioscience & Biotechnology;Feb2014, Vol. 5 Issue 3, p184 

    In current article, results of the determination of the concentrations of vascular endothelial growth factor (VEGF), and some interleukins (IL-4, IL-6, IL-10, IL-17A) in the vitreous of patients with proliferative diabetic retinopathy are presented. We have found that in the mechanism of...

  • Effect of Intravitreal Bevacizumab on Vascular Endothelial Growth Factor Expression in Patients with Proliferative Diabetic Retinopathy.  // Yonsei Medical Journal;1/1/2011, Vol. 52 Issue 1, p151 

    No abstract available.

  • A review of anti-VEGF agents for proliferative diabetic retinopathy. Osaadon, P; Fagan, X J; Lifshitz, T; Levy, J // Eye;May2014, Vol. 28 Issue 5, p510 

    Previous research has implicated vascular endothelial growth factor (VEGF) in the pathogenesis of diabetic retinopathy (DR). Although many studies reviewed the use of anti-VEGF for diabetic macular oedema, little has been written about the use of anti-VEGF for proliferative diabetic retinopathy...

  • Update: Treatments for Diabetic Retinopathy. Reinauer, Robert; Amde, Wendewessen; Tewari, Astieesh // Review of Ophthalmology;Oct2011, Vol. 18 Issue 10, p58 

    The article discusses several treatments for diabetic macular edema (DME) including intravitreal corticosteroids, anti-vascular endothelial growth factor (VEGF) agents, and the surgical procedure. It mentions that intravitreal steroid delivery system releases small amount of steroid to lessen...

  • Diabetic Retinopathy. Gómez-Ulla, Francisco // Current Diabetes Reviews;2009, Vol. 5 Issue 1, p1 

    The article discusses various reports published within the issue, including one by Monica Rodriguez-Fontal et al on the importance of metabolic control in managing diabetic retinopathy, one by Talia N. Crawford et al on the role of angiogenic factors in diabetic retinopathy and another one by...

  • Vascular Endothelial Growth Factor in the Vitreous of Proliferative Diabetic Retinopathy Patients: Chasing a Hiding Prey? Rezzola, Sara; Nawaz, Mohd I.; Cancarini, Anna; Semeraro, Francesco; Presta, Marco // Diabetes Care;Jul2019, Vol. 42 Issue 7, pe105 

    The article discusses a 2019 study on vascular endothelial growth factor (VEGF) in the vitreous of proliferative diabetic retinopathy (PDR) patients. Results show that vitreal components may contribute to the creation of noncovalent enzyme-linked immunosorbent assay- (ELISA) masking VEGF...

Share

Read the Article

Courtesy of THE LIBRARY OF VIRGINIA

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics